| Response Genetics

Skip to Main Content

Search:

Company
ResponseDX™
Products & Services
Our Technology
Investor Relations
CLIA & GLP
News
Contact

Response Genetics PCR-based genetic tests--ResponseDX: Lung™ and ResponseDX: Colon™--provide personalized genetic information that will help guide cancer patients and doctors in choosing the most beneficial treatment options for patients.

This test helps identify NSCLC patients who may benefit from tyrosine kinase inhibitor (TKI) therapy. For information about ordering EGFR mutation analysis, click here or call (888) 700-7110.

Response Genetics Reports Second Quarter 2007 Financial Results, Response Genetics Study to Focus on Developing Diagnostic Test Kits for Pancreatic Cancer

Company | ResponseDX™| Products & Services | Our Technology | Investor Relations | CLIA & GLP | News | Contact | Terms of Use | Privacy Policy
© Response Genetics, Inc. All rights reserved.